Review Of Reviews: Drug Review Profiles Of 2011
This article was originally published in Pharmaceutical Approvals Monthly
Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.
You may also be interested in...
Fibrocell’s autologous cell therapy Laviv was reviewed by CBER with significant help from CDER and CDRH, providing a model of how FDA can handle high-tech products that cross traditional boundaries.
Absence of data about what happens under the surface of the skin when the cell therapy for wrinkles is injected raised safety concerns.
FDA approved Bristol-Myer’s Squibb’s metastatic melanoma immunotherapy Yervoy (ipilimumab) only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.